Business Context and Reporting Period
This Form 8-K was filed by Elevai Labs, Inc. (ELAB) on November 28, 2023, reporting a material event that occurred on the same date. The registrant is an emerging growth company incorporated in Delaware, with principal executive offices in Newport Beach, California. The filing primarily addresses the entry into a Material Definitive Agreement.
Key Financial Metrics
This filing does not contain comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial figure disclosed relates to the new agreement:
- Upfront Payment: $5,000 paid to Yuva BioSciences, Inc. as consideration for rights granted under the Collaboration Agreement.
- Cost Assumption: The Company has assumed all costs associated with the development, manufacture, and commercialization of the licensed product.
Material Changes
The material change reported is the execution of a Collaboration and License Agreement with Yuva BioSciences, Inc. Key terms include:
- Scope: Collaboration on research, development, manufacture, and commercialization of a new cosmetic product for Elevai's aesthetics skincare offerings.
- Intellectual Property: Elevai received non-exclusive, nontransferable, royalty-bearing rights to Yuva's proprietary compound, potentially combined with Elevai's exosome-based ingredients.
- Joint Trials: Joint trials are scheduled to be conducted within the initial six months to evaluate the compound's effect on skin appearance.
- Geographic Territory: United States, Canada, and other mutually agreed territories.
Guidance, Outlook, and Risks
Outlook and Obligations: The Company is obligated to pay royalties based on two structures: (i) a minimum royalty for five years following the completion of joint trials, and (ii) earned royalties on net sales for a period lasting the latter of eight years from the agreement date, patent expiration, or ten years after the first commercialization date.
Risks and Contingencies: The agreement includes specific termination rights for Yuva if Elevai fails to meet certain milestones:
- Failure to take measurable commercialization actions, develop draft marketing materials, or pay minimum royalties within one year of joint trial completion.
- No net sales accrued by the second anniversary of joint trial completion.
- Failure to exert commercially reasonable efforts in development or commercialization.
- Upon termination, all licenses granted to Elevai will terminate.
Management Commentary: The filing incorporates a press release issued on November 29, 2023, regarding the agreement. No additional forward-looking guidance on financial performance was provided in this document.
Investor Verification Checklist
- Verify the filing of the full Collaboration Agreement as an exhibit to the Form 10-Q for the quarter ended September 30, 2023, noting that certain confidential information may be redacted.
- Monitor the progress of the joint trials scheduled for the first six months of the agreement.
- Assess the Company's ability to meet the minimum royalty obligations and commercialization milestones to avoid termination by Yuva.
- Review the press release (Exhibit 99.1) for additional details on the strategic rationale for the partnership.